Chinese biotech firm Biocytogen bags $142m Series D+ led by CMB International

Chinese biotech firm Biocytogen bags $142m Series D+ led by CMB International

Gut microbiome. Credit: Natural Health 365

Beijing-based biotechnology platform Biocytogen has announced the completion of a 970 million yuan ($142 million) Series D+ round led by returning backer CMB International, a Hong Kong-based subsidiary of China Merchants Bank.